「anti」の検索結果

Eliminate sycophantic agreement patterns in AI responses. Load via /skill anti-sycophancy.

日本語の概要は準備中です。原文の説明を表示しています。

Use when the user asks to "design an early access program", "set up a waitlist and beta stages", or "define beta graduation criteria"; produces a waitlist→concept→alpha→beta→GA stage ladder with per-stage purpose and opt-in semantics, quantified graduation criteria per stage (labeled Estimated), a cohort-gating and invite-throttling plan, tester recruitment with launch-day social-proof prep, a feedback-loop spec where every status change notifies its subscribers, and a referral-loop mechanism spec (invite codes, anti-abuse). Not for waitlist acquisition strategy or the capture-flow spec — use list-growth-designer; not for the canonical stage record — use launch-registry. waitlist/内测阶梯/抢先体验/毕业标准/反馈闭环

日本語の概要は準備中です。原文の説明を表示しています。

Front the studio as Manny the Manticore. Use when the user says "Manny", "Manticore", or "talk to Manny".

日本語の概要は準備中です。原文の説明を表示しています。

Understand anti-reversing, obfuscation, and protection techniques encountered during software analysis. Use when analyzing protected binaries, bypassing anti-debugging for authorized analysis, or u...

日本語の概要は準備中です。原文の説明を表示しています。

Orchestrate multiple Antigravity skills through guided workflows for SaaS MVP delivery, security audits, AI agent builds, and browser QA.

日本語の概要は準備中です。原文の説明を表示しています。

Understand anti-reversing, obfuscation, and protection techniques encountered during software analysis. Use this skill when analyzing malware evasion techniques, when implementing anti-debugging protections for CTF challenges, when reverse engineering packed binaries, or when building security research tools that need to detect virtualized environments.

日本語の概要は準備中です。原文の説明を表示しています。

Expert Antigravity Code (Gemini IDE, développement agentic, IA-assisté, workflows)

日本語の概要は準備中です。原文の説明を表示しています。

Catalog of MSBuild anti-patterns with detection rules and fix recipes. Only activate in MSBuild/.NET build context. USE FOR: reviewing, auditing, or cleaning up .csproj, .vbproj, .fsproj, .props, .targets, or .proj files. Each anti-pattern has a symptom, explanation, and concrete BAD→GOOD transformation. Covers Exec-instead-of-built-in-task, unquoted conditions, hardcoded paths, restating SDK defaults, scattered package versions, and more. DO NOT USE FOR: non-MSBuild build systems (npm, Maven, CMake, etc.), project migration to SDK-style (use msbuild-modernization).

日本語の概要は準備中です。原文の説明を表示しています。

Guide for MSBuild extensibility: CustomBefore/CustomAfter hooks, wildcard imports with alphabetic ordering, import gating with control properties, NuGet package build extension layout (build/buildTransitive), and the MicrosoftCommonPropsHasBeenImported guard. Only activate in MSBuild/.NET build context. USE FOR: diagnosing and fixing MSBuild import and hook patterns, reviewing and fixing extension point anti-patterns in Directory.Build files, fixing missing Exists() guards on imports that break fresh clones, fixing NuGet package hooks being silently dropped instead of appended, making build targets extensible for other projects, injecting custom logic into the build pipeline, creating NuGet packages that extend the build, conditionally disabling imports. DO NOT USE FOR: target authoring patterns (use target-authoring), props vs targets placement (use directory-build-organization), general anti-patterns (use msbuild-antipatterns), non-MSBuild build systems.

日本語の概要は準備中です。原文の説明を表示しています。

Canonical patterns for writing custom MSBuild targets. Only activate in MSBuild/.NET build context. USE FOR: diagnosing and fixing custom target authoring anti-patterns, reviewing MSBuild target definitions for correctness, diagnosing broken SDK target chains across files (e.g., Directory.Build.targets silently redefining SDK targets), fixing targets that replace CompileDependsOn instead of extending it with $(CompileDependsOn), fixing query targets that return stale results due to Outputs vs Returns misuse, fixing missing Inputs/Outputs causing unnecessary rebuilds, fixing missing FileWrites registration. Covers DependsOnTargets vs BeforeTargets vs AfterTargets, the Build→CoreBuild three-level pattern, hooking into the build pipeline, the $(XxxDependsOn) chain-extension pattern. DO NOT USE FOR: incremental build tuning (use incremental-build), parallelization (use build-parallelism), general anti-patterns (use msbuild-antipatterns), non-MSBuild build systems.

日本語の概要は準備中です。原文の説明を表示しています。

Anti-debug bypass ve obfuscation çözme — ptrace, UPX, PRNG, packer tespiti

日本語の概要は準備中です。原文の説明を表示しています。

Post-training 4-bit quantization for LLMs with minimal accuracy loss. Use for deploying large models (70B, 405B) on consumer GPUs, when you need 4× memory reduction with <2% perplexity degradation, or for faster inference (3-4× speedup) vs FP16. Integrates with transformers and PEFT for QLoRA fine-tuning.

日本語の概要は準備中です。原文の説明を表示しています。

GGUF format and llama.cpp quantization for efficient CPU/GPU inference. Use when deploying models on consumer hardware, Apple Silicon, or when needing flexible quantization from 2-8 bit without GPU requirements.

日本語の概要は準備中です。原文の説明を表示しています。

Designs and validates quantitative targeted metabolomics assays (MRM/SRM on triple-quadrupole, PRM on high-resolution instruments) to report absolute concentrations. Covers the internal-standard strategy (external cal -> global IS -> standard addition -> stable-isotope-labeled IS), weighted calibration judged by back-calculated %RE not R-squared, ion-ratio quantifier/qualifier confirmation, matrix-effect/recovery characterization, and ICH M10 method validation. Use when quantifying a closed panel of known metabolites with units, building or validating an LC-MS/MS assay, choosing an IS or calibration weighting, or judging whether a reported concentration is trustworthy. For untargeted feature detection see metabolomics/xcms-preprocessing; for group statistics see metabolomics/statistical-analysis; for flux/MID/tracing see metabolomics/isotope-tracing.

日本語の概要は準備中です。原文の説明を表示しています。

Identify tumor neoantigens from somatic variants with pVACtools (pVACseq/pVACfuse/pVACbind/pVACvector/pVACview) for personalized cancer vaccines and checkpoint biomarkers. Encodes the field's hard truth that binding prediction is the easy, near-solved part and single-digit-percent PPV lives downstream — so it centers clonality/CCF, HLA LOH (the silent invalidator), expression, proximal-variant phasing, agretopicity/foreignness quality, and the predicted->presented->immunogenic validation tiers. Use when nominating vaccine targets, ranking neoantigens, or building a tumor-to-candidate pipeline. Binding details in mhc-binding-prediction; ranking in immunogenicity-scoring.

日本語の概要は準備中です。原文の説明を表示しています。

Quantifies CRISPR editing outcomes with CRISPResso2 (Clement 2019 Nat Biotechnol) across Cas9-nuclease (indels, HDR), CBE and ABE base editors (target conversion + bystander), and prime editor (pegRNA-templated) modes. Covers single-amplicon (CRISPResso), multi-sample batch (CRISPRessoBatch), pooled-amplicon (CRISPRessoPooled), WGS off-target (CRISPRessoWGS), and sample-comparison (CRISPRessoCompare) workflows; quantification-window math that controls what is called edited; substitution-vs-indel diagnostic to distinguish BE from Cas9 contamination; MMEJ deletion pattern interpretation; allele-frequency tables; and failure modes from amplicon misalignment or contamination. Use when quantifying editing from amplicon sequencing, choosing CRISPResso mode by design, distinguishing intended edits from bystanders and indel byproducts, debugging low-alignment runs, or generating publication-grade editing reports.

日本語の概要は準備中です。原文の説明を表示しています。

Map N6-methyladenosine (m6A) RNA modifications at single-nucleotide resolution using miCLIP (Linder 2015), miCLIP2 + m6Aboost machine learning (Kortel 2021), GLORI (Liu 2023, antibody-free chemical conversion), DART-seq (Meyer 2019, APOBEC1-YTH fusion), m6Anet (nanopore direct RNA), or MeRIP-seq with calibration. Use when distinguishing antibody-based from antibody-free m6A detection methods, applying the DRACH motif constraint, reconciling cross-method disagreements (DART 44% in DRACH vs GLORI), or detecting m6Am at the cap.

日本語の概要は準備中です。原文の説明を表示しています。

Profiles RNA-binding protein targets without antibody or UV crosslinking using STAMP (APOBEC1-RBP fusion, C-to-U editing), scSTAMP (single-cell), TRIBE/HyperTRIBE (ADAR-RBP, A-to-I editing), DART-seq (APOBEC1-YTH for m6A), or Bullseye/SAILOR edit-site detection pipelines. Use when antibody is unavailable or specificity is doubtful, when single-cell RBP profiling is needed (scSTAMP), or when in vivo RBP profiling without UV is preferred.

日本語の概要は準備中です。原文の説明を表示しています。

Eliminate sycophantic agreement patterns in AI responses. Load via /skill anti-sycophancy.

日本語の概要は準備中です。原文の説明を表示しています。

Configure and orchestrate parallel agents using the standalone Antigravity 2.0 Agent Manager and Antigravity IDE.

日本語の概要は準備中です。原文の説明を表示しています。

Identify tumor neoantigens from somatic variants with pVACtools (pVACseq/pVACfuse/pVACbind/pVACvector/pVACview) for personalized cancer vaccines and checkpoint biomarkers. Encodes the field's hard truth that binding prediction is the easy, near-solved part and single-digit-percent PPV lives downstream — so it centers clonality/CCF, HLA LOH (the silent invalidator), expression, proximal-variant phasing, agretopicity/foreignness quality, and the predicted->presented->immunogenic validation tiers. Use when nominating vaccine targets, ranking neoantigens, or building a tumor-to-candidate pipeline. Binding details in mhc-binding-prediction; ranking in immunogenicity-scoring.

日本語の概要は準備中です。原文の説明を表示しています。

Quantifies CRISPR editing outcomes with CRISPResso2 (Clement 2019 Nat Biotechnol) across Cas9-nuclease (indels, HDR), CBE and ABE base editors (target conversion + bystander), and prime editor (pegRNA-templated) modes. Covers single-amplicon (CRISPResso), multi-sample batch (CRISPRessoBatch), pooled-amplicon (CRISPRessoPooled), WGS off-target (CRISPRessoWGS), and sample-comparison (CRISPRessoCompare) workflows; quantification-window math that controls what is called edited; substitution-vs-indel diagnostic to distinguish BE from Cas9 contamination; MMEJ deletion pattern interpretation; allele-frequency tables; and failure modes from amplicon misalignment or contamination. Use when quantifying editing from amplicon sequencing, choosing CRISPResso mode by design, distinguishing intended edits from bystanders and indel byproducts, debugging low-alignment runs, or generating publication-grade editing reports.

日本語の概要は準備中です。原文の説明を表示しています。

Map N6-methyladenosine (m6A) RNA modifications at single-nucleotide resolution using miCLIP (Linder 2015), miCLIP2 + m6Aboost machine learning (Kortel 2021), GLORI (Liu 2023, antibody-free chemical conversion), DART-seq (Meyer 2019, APOBEC1-YTH fusion), m6Anet (nanopore direct RNA), or MeRIP-seq with calibration. Use when distinguishing antibody-based from antibody-free m6A detection methods, applying the DRACH motif constraint, reconciling cross-method disagreements (DART 44% in DRACH vs GLORI), or detecting m6Am at the cap.

日本語の概要は準備中です。原文の説明を表示しています。

Profiles RNA-binding protein targets without antibody or UV crosslinking using STAMP (APOBEC1-RBP fusion, C-to-U editing), scSTAMP (single-cell), TRIBE/HyperTRIBE (ADAR-RBP, A-to-I editing), DART-seq (APOBEC1-YTH for m6A), or Bullseye/SAILOR edit-site detection pipelines. Use when antibody is unavailable or specificity is doubtful, when single-cell RBP profiling is needed (scSTAMP), or when in vivo RBP profiling without UV is preferred.

日本語の概要は準備中です。原文の説明を表示しています。